Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B) reported no changes in its equity structure for the month ended 31 August 2026, according to the company’s monthly return filed with Hong Kong Exchanges and Clearing Limited on 4 September 2026.

Key highlights

1. Authorised and issued share capital • Authorised/registered share capital remained unchanged at RMB 170.55 million, representing 170.55 million H-shares with a par value of RMB 1.00 each. • Issued shares stood at 170.55 million, of which 569,400 shares are held as treasury shares. The issued free-float of 169.99 million shares was unchanged versus the prior month.

2. Public float compliance The company confirmed compliance with Main Board Rule 13.32D, maintaining at least the initial prescribed public float threshold of 15.61 % of total issued shares (excluding treasury shares).

3. Share option position • Outstanding options under the Pre-IPO Share Option Scheme total 2.11 million, carrying an exercise price of RMB 3.70 per share. • No options vested, exercised or cancelled during the month. Vesting begins 9 January 2028, 24–36 months after the listing date (9 January 2026). • The option pool does not currently permit the issue or transfer of additional shares beyond those already granted.

4. No other equity instruments The company reported no warrants, convertibles, or other equity-linked instruments and recorded no share repurchases, cancellations, or transfers from treasury in August 2026.

Implications The absence of share movements preserves RIBOLIFE-B’s capital structure and mitigates dilution risk ahead of the 2028 option vesting window. Continued adherence to public float requirements supports liquidity and regulatory compliance.